+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Duchenne Muscular Dystrophy Drugs Market by Drug Class, Distribution Channel, End User, Form, Route of Administration - Global Forecast to 2030- Product Image
Duchenne Muscular Dystrophy Drugs Market by Drug Class, Distribution Channel, End User, Form, Route of Administration - Global Forecast to 2030- Product Image
Sale

Duchenne Muscular Dystrophy Drugs Market by Drug Class, Distribution Channel, End User, Form, Route of Administration - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967658
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Duchenne muscular dystrophy drugs market is experiencing rapid transformation as therapeutic innovation, evolving regulatory priorities, and shifting global trade policies influence care pathways and commercial strategies.

Market Snapshot: Duchenne Muscular Dystrophy Drugs Market

The Duchenne muscular dystrophy drugs market grew from USD 1.70 billion in 2024 to USD 1.85 billion in 2025. It is expected to continue growing at a CAGR of 8.65%, reaching USD 2.80 billion by 2030. Driven by major scientific breakthroughs, therapeutic options continue to expand as industry players adapt to meet varied patient and regulatory needs. As these pharmaceutical advancements align with shifting payer expectations, the landscape is evolving with new gene therapies and targeted therapies entering clinical use, signaling sustained growth and increasing competitiveness across the sector.

Scope & Segmentation

This analysis provides a comprehensive breakdown across technologies, therapy types, delivery channels, care settings, product forms, and regions.

  • Drug Class: Exon skipping agents, gene therapies (adeno-associated virus-based and nonviral), and steroid therapies.
  • Distribution Channels: Hospital, online, and retail pharmacies support diverse dispensing and administration needs.
  • End Users: Home healthcare settings, hospitals, and specialty clinics represent the main environments for therapy administration.
  • Form: Capsules, injectables, and oral tablets cater to prescriber and patient preferences.
  • Route of Administration: Intramuscular, intravenous, and oral modes address unique clinical requirements.
  • Regional Coverage: Americas (including United States, Canada, and several Latin American countries), Europe, Middle East & Africa (covering both established and emerging markets), and Asia-Pacific (with significant presence in East Asia, South Asia, and Oceania).
  • Key Companies Profiled: Industry leaders such as Sarepta Therapeutics, Pfizer, BioMarin Pharmaceutical, Roche Holding, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma.

Key Takeaways for Strategy and Leadership

  • Therapeutic innovation is changing the standard of care, with new modalities such as gene therapy and exon skipping providing disease-modifying options beyond traditional symptom management.
  • Regulatory acceleration—such as priority review and fast-track designations—enables faster market entry for advanced therapeutics, but also requires robust evidence generation to support long-term adoption.
  • Multichannel distribution and adaptive supply chain strategies are critical for ensuring timely and efficient access amid fluctuating input costs and logistical disruptions.
  • Patient engagement and digital monitoring tools are enhancing care delivery, enabling decentralized trials, and generating real-world data to inform payers and prescribers.
  • Regional access disparities are shaped by local regulatory frameworks, payer infrastructure, and healthcare investment, requiring tailored geographic expansion and stakeholder engagement strategies.

Tariff Impact: Managing New Trade Pressures

The introduction of United States tariffs in 2025 is altering input costs and prompting manufacturers to reconsider sourcing and manufacturing strategies. Increased duties on key components are shifting some production processes onshore and driving partnerships with domestic contract manufacturing organizations. These changes require significant capital and operational adjustments, as well as new approaches for navigating complex payer negotiations and maintaining pricing competitiveness.

Methodology & Data Sources

This research employs a rigorous, multi-stage methodology. It combines extensive secondary analysis (peer-reviewed publications, regulatory filings, and company disclosures) with primary interviews from industry experts, payers, and key opinion leaders. Segmentation is validated through triangulated quantitative and qualitative data, with a peer review process to ensure accuracy and transparency across each segment.

Why This Report Matters

  • Enables executives to align product, distribution, and investment strategies with evolving therapeutic and regulatory trends.
  • Supports market access, pricing, and competitive positioning decisions through actionable segmentation and detailed regional analysis.

Conclusion

The Duchenne muscular dystrophy drugs market is evolving with breakthrough therapies and changing operational realities. Leaders equipped with segment-level insights and strategic recommendations will be better prepared to achieve sustained growth and respond effectively to emerging challenges.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Duchenne Muscular Dystrophy Drugs Market, by Drug Class
8.1. Introduction
8.2. Exon Skipping
8.3. Gene Therapy
8.3.1. Aav Based
8.3.1.1. Serotype 6
8.3.1.2. Serotype 9
8.3.2. Nonviral
8.4. Steroid Therapy
9. Duchenne Muscular Dystrophy Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Duchenne Muscular Dystrophy Drugs Market, by End User
10.1. Introduction
10.2. Home Healthcare Settings
10.3. Hospitals
10.4. Specialty Clinics
11. Duchenne Muscular Dystrophy Drugs Market, by Form
11.1. Introduction
11.2. Capsule
11.3. Injectable
11.4. Oral Tablet
12. Duchenne Muscular Dystrophy Drugs Market, by Route of Administration
12.1. Introduction
12.2. Intramuscular
12.3. Intravenous
12.4. Oral
13. Americas Duchenne Muscular Dystrophy Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Duchenne Muscular Dystrophy Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Sarepta Therapeutics, Inc.
16.3.2. Pfizer Inc.
16.3.3. BioMarin Pharmaceutical Inc.
16.3.4. Roche Holding AG
16.3.5. Bayer Aktiengesellschaft
16.3.6. Solid Biosciences, Inc.
16.3.7. Cytokinetics, Inc.
16.3.8. NS Pharma, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET MULTI-CURRENCY
FIGURE 2. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 50. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 51. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 54. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 57. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 58. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 61. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 93. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 94. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 97. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 100. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 101. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 104. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 114. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 115. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 118. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 121. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 122. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 125. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 149. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 150. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 153. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 163. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 164. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 167. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 170. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 171. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 174. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 191. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 192. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 195. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 197. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 198. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 199. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 202. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 211. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 212. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 213. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 216. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 218. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 219. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 220. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 223. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 239. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 241. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 242. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 245. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 248. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 249. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 252. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 254. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 255. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 256. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 259. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 282. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 283. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 284. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 287. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Duchenne Muscular Dystrophy Drugs market report include:
  • Sarepta Therapeutics, Inc.
  • Pfizer Inc.
  • BioMarin Pharmaceutical Inc.
  • Roche Holding AG
  • Bayer Aktiengesellschaft
  • Solid Biosciences, Inc.
  • Cytokinetics, Inc.
  • NS Pharma, Inc.

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.85 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.8 Billion
Compound Annual Growth Rate8.6%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Duchenne Muscular Dystrophy Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032 - Product Image

Duchenne Muscular Dystrophy Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032

  • Report
  • 172 Pages
  • Global
From
Duchenne Muscular Dystrophy Drugs - Global Strategic Business Report - Product Image

Duchenne Muscular Dystrophy Drugs - Global Strategic Business Report

  • Report
  • 220 Pages
  • Global
From
Duchenne Muscular Dystrophy Market Report 2025 - Product Image

Duchenne Muscular Dystrophy Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Duchenne Muscular Dystrophy Drugs Global Market Report 2025 - Product Image

Duchenne Muscular Dystrophy Drugs Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Duchenne Muscular Dystrophy Drugs Market by Product Type, Therapeutic Approach, End User, and Region 2025-2033 - Product Image

Duchenne Muscular Dystrophy Drugs Market by Product Type, Therapeutic Approach, End User, and Region 2025-2033

  • Report
  • 143 Pages
  • Global
From

About the Market

Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder that affects the muscles and is caused by a mutation in the dystrophin gene. It is the most common form of muscular dystrophy and is characterized by progressive muscle weakness and loss of muscle mass. Treatment for DMD is limited to supportive care and the use of certain drugs to slow the progression of the disease. Central Nervous System (CNS) drugs are used to treat the symptoms of DMD, such as muscle spasms, pain, and fatigue. These drugs can also help to improve the quality of life of those affected by the disorder. The DMD drug market is a rapidly growing segment of the CNS drug market. It is estimated that the global DMD drug market will reach $2.5 billion by 2027, driven by the increasing prevalence of DMD and the development of new drugs. Several companies are involved in the development and commercialization of DMD drugs, including Sarepta Therapeutics, Pfizer, GlaxoSmithKline, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.